-
Posted by
Two Blokes Jun 28 -
Filed in
Stock
-
7 views
On June 24, Nektar Therapeutics NASDAQ: NKTR stock exploded nearly 157% following news that Rezpeg, the company's experimental treatment for atopic dermatitis (eczema), successfully met its primary and secondary goals in a Phase 2b trial. Nektar joined a wave of micro-cap biotechnology stocks surging after promising clinical trial results.
